Elevation Oncology (ELEV) has released an update to notify the public and investors about its officers.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Elevation Oncology, Inc. appointed Darcy Mootz, Ph.D., as a Class II director and member of the Compensation Committee effective immediately, with her term set to expire at the 2026 annual stockholders’ meeting. Dr. Mootz, who declared independent by the Board per SEC and Nasdaq rules, is the current President of Architect Therapeutics and holds a B.S. from Duke and a Ph.D. from Harvard. She has extensive experience in the pharmaceutical industry, including leadership roles at Amunix Pharmaceuticals and ORIC Pharmaceuticals, and sits on the board of Alpha-9 Oncology. Dr. Mootz has been granted an initial stock option, will receive an annual retainer for her board service, and has entered into a standard indemnity agreement with the Company.
For further insights into ELEV corporate activity, check out TipRanks’ Insiders Trading Activity page.
